ARTICLE | Company News
Aphios other research news
August 17, 1998 7:00 AM UTC
Aphios received a $100,000 Phase I SBIR from the National Institute of Allergy and Infectious Diseases to develop a therapeutic HIV vaccine combining its attenuated HIV particles (including HIV lackin...